Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5334 - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Ovarian Cancer;  Breast Cancer

Presenters

Angela George

Citation

Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250

Authors

A. George1, F. Chilcott1, C. Pate1, S. Banerjee2

Author affiliations

  • 1 Medical Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Department Of Gynaecology, The Royal Marsden Hospital NHS Foundation Trust and Institute of Cancer Research, SW3 6JJ - London/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5334

Background

Women with OC due to an underlying BRCAm have enhanced responses to platinum and often improved progression free survival. BRCAm carriers also have an increased risk of BC, which often predates OC and may impact later treatment response.

Methods

Women with OC treated at The Royal Marsden Hospital between 01/06/13 and 31/5/17 with known BRCAm status were identified from the electronic patient record. The primary endpoint was progression free survival (PFS) after first line treatment for OC, stratified for BRCAm and BC status. Secondary endpoints were time to second subsequent treatment (TSST) and type of BRCA mutation (BRCA1 vs BRCA2).

Results

575 patients were identified, 502 high grade (HG), 73 low grade (LG) OC. Histology was HG serous (77%), endometroid (10%), clear cell (5%), LG serous (4%), other (4%). 158 (27%) had a BRCAm, 92 (58%) BRCA1 and 66 (42%) BRCA2. Mean age of OC diagnosis was 59 (19-98) yrs. Prior BC was noted in 79 patients – 51 BRCAm, 28 WT; 21 patients had >1 BC (14 BRCA, 7 WT). Mean age of first BC diagnosis was 50 yrs (30-75). Median PFS (mths) was 19.6 (BC, WT) vs 23.6 (no BC, WT) vs 25.4 (BC, BRCAm) vs 27.1 (no BC, BRCAm), p = 0.08. TSST(mths) was significantly different at 23.1 (BC, WT) vs 30 (no BC, WT) vs 34 (BC, BRCAm) vs 42.6 (no BC, BRCAm), p = 0.02. There was no significant difference in PFS between those who did/did not receive chemotherapy for prior breast cancer; nor between those with a BRCA1 vs BRCA2 mutation.

Conclusions

Within the limits of a retrospective audit, there was no significant difference in PFS for women with OC irrespective of prior BC diagnosis or BRCAm status, but there was a significant difference in TSST. A similar trend was seen in both groups, with poorest PFS/TSST in those with prior BC/BRCA WT; and best PFS/TSST in those with no prior BC/BRCAm. Prior BC diagnosis may be another factor in response to OC chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.